People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.
Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...
Dyskinesia is when you experience involuntary movements. Chorea is one type of dyskinesia. It is associated with health conditions like Huntington’s disease, infection, or side effects of medications.
Dyskinesia is a state in which someone experiences involuntary movements. Chorea is a type of dyskinesia. Other types of dyskinesia include tics, myoclonus, dystonia, and akathisia. There are ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA approved Ingrezza due to results from KINECT-HD, ...
Chorea and hemiballismus are both forms of involuntary movement disorders. Hemiballismus can cause sudden, violent, and flinging motions. Chorea can cause irregular, spontaneous, and nonrepetitive ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...
Credit: Getty Images. Valbenazine 40mg achieved greater placebo-adjusted improvement in chorea as early as week 2 and sustained greater efficacy through week 12 compared with placebo. Valbenazine ...
A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington’s disease, according to a recent international study led by UTHealth Houston researcher Erin Furr ...
A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...
The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD. Positive topline data were announced from a phase 3 study evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback